FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms-Reference-Cited by-同舟云学术

FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms

Published:2022 Issue:7 Volume:13 Page:798-816
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Acharya Baku¹,Saha Debasmita¹,Armstrong Daniel¹,Lakkaniga Naga Rajiv²,Frett Brendan¹^ORCID

Affiliation:

1. Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA

2. Department of Chemistry and Chemical Biology, Indian Institute of Technology (Indian School of Mines), Dhanbad, Jharkhand 826004, India

Abstract

Numerous precision medicine therapies for AML have been investigated, but the disease remains difficult to target. Therapies that block common resistance mechanisms are needed to improve treatment durability.

Funder

National Institute of General Medical Sciences

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2022/MD/D2MD00067A

Reference131 articles.

1. The roles of FLT3 in hematopoiesis and leukemia

2. Genomic structure of the downstream part of the human FLT3 gene: exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III

3. FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular precision medicine: Multi-omics-based stratification model for acute myeloid leukemia;Heliyon;2024-09

2. Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases;Pharmacological Research;2024-01

3. Identification of a Selective FLT3 Inhibitor with Low Activity against VEGFR, FGFR, PDGFR, c‐KIT, and RET Anti‐Targets;ChemMedChem;2023-12-07

4. Imidazopyridine-based kinase inhibitors as potential anticancer agents: A review;Bioorganic Chemistry;2023-11

5. A Comprehensive Review of Systemic Targeted Therapies in Cancer Treatment;Current Cancer Therapy Reviews;2023-10-25